GlobeImmune's Hepatitis C Product Candidate Improves End of Treatment Response in All IL-28 B Genotypes, With the Greatest Effect in the Hardest-to-Treat Patients LOUISVILLE, CO--(Marketwire - April 19, 2010) -  GlobeImmune Inc. announced Phase 2b data for GI-5005, the Company's investigational Tarmogen® product for hepatitis C virus (HCV) infection,...

GlobeImmune GI-5005 HCV Product Candidate Improves Sustained Virologic Response by 10 Percent, Demonstrating Potential to Be First Therapeutic Vaccine for HCV LOUISVILLE, CO--(Marketwire - April 15, 2010) -  GlobeImmune, Inc. today announced final Phase 2b data for GI-5005, the Company's investigational Tarmogen® product candidate, demonstrating...